Literature DB >> 2497646

Norplant: subdermal implant system for long-term contraception.

D Shoupe1, D R Mishell.   

Abstract

Norplant offers long-term contraception through the use of subdermal capsules filled with levonorgestrel. The six capsules are implanted in the inside part of the upper arm. The levonorgestrel is released from the capsules gradually, providing contraception for about 5 years. The primary mechanism of action of Norplant is suppression of ovulation. Studies have shown a pregnancy rate of 0.6/100 woman-years after 1 year and a cumulative rate of 1.5/100 woman-years at 5 years. Principal side effects are irregular menstrual bleeding and headaches. No changes in carbohydrate metabolism, blood coagulation, or liver function have been reported. Lipid levels have decreased 5% to 15%. After removal of Norplant, fertility returns rapidly, and there have been no adverse effects on infants. Norplant is currently approved in 12 countries; clinical trials are being conducted in 37 countries.

Entities:  

Keywords:  Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Effectiveness; Contraceptive Implants; Contraceptive Methods; Demographic Factors; Evaluation; Family Planning; Fertility; Fertility Measurements; Levonorgestrel--side effects; Literature Review; Population; Population Dynamics; Pregnancy Rate; Qualitative Evaluation; Use-effectiveness

Mesh:

Substances:

Year:  1989        PMID: 2497646     DOI: 10.1016/s0002-9378(89)80014-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Progestin-only contraception.

Authors:  E Beck
Journal:  West J Med       Date:  1991-03

3.  Nitric oxide (NO)-induced death of gram-negative bacteria from a light-controlled NO-releasing platform.

Authors:  Genevieve M Halpenny; Brandon Heilman; Pradip K Mascharak
Journal:  Chem Biodivers       Date:  2012-09       Impact factor: 2.408

4.  Norplant selection and satisfaction among low-income women.

Authors:  L L Clarke; K Schmitt; C A Bono; J Steele; M K Miller
Journal:  Am J Public Health       Date:  1998-08       Impact factor: 9.308

5.  Differential off-target glucocorticoid activity of progestins used in endocrine therapy.

Authors:  Maleshigo Komane; Chanel Avenant; Renate Louw-du Toit; Donita J Africander; Janet P Hapgood
Journal:  Steroids       Date:  2022-03-07       Impact factor: 2.760

6.  Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.

Authors:  W H Catherino; M H Jeng; V C Jordan
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.